Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter


Achieved net product revenues of $19.7 million for the fourth quarter of 2023 representing 35% year on...

Related Keywords

Pavel Raifeld ,Matthew Ronsheim ,Armata Pharmaceuticals ,Jolla Pharmaceutical Company ,Securities Exchange ,Glaxo Group Limited ,Innoviva Inc ,Nasdaq ,Drug Administration ,Global Antibiotic Research Development Partnership ,Exchange Commission ,Innoviva Specialty Therapeutics ,Chief Executive Officer ,Product Sales ,Global Antibiotic Research ,Development Partnership ,New Drug Application ,Lancet Infectious Diseases ,Strategic Healthcare ,Gate Neurosciences ,Entasis Therapeutics ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Financial Condition ,Annual Report ,Quarterly Reports ,Consolidated Statements ,Ended December ,